R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
A Study of ARC-02 in B-cell NHL
- Status
- RECRUITING
- Phase
- PHASE1
Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
The CARDIOPROTECT Trial
- Status
- RECRUITING
- Phase
- PHASE2
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2